A Phase 2/3 interventional study of docetaxel (XRP6976) and cisplatin in Head and Neck Neoplasms, Neoplasm Recurrence, Local and Neoplasm Metastasis, sponsored by Sanofi. Completed at 20 sites in 20 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-01-20.
Sponsored by Sanofi · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies testing docetaxel in Head and Neck Neoplasms — 3 open to participants now, 6 under way, none of them phase 3. Docetaxel · Head and Neck Neoplasms.
Among the 68 studies testing docetaxel in Head and Neck Neoplasms, this one has the largest enrollment of the 64 interventional ones that give a count, is one of 2 that started in 1998, is the only one in phase 2/3, and was the 27th registered.
2,713 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →3 of the 68 studies testing docetaxel in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–75
Assiut University
Ages 19+
By country, each count listing its studies:
Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 47 · Phase 3 6 · Phase 4 2
First in 1995; this study’s year is marked. 2 started in 1998.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 568 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 34 across the 64 interventional studies. Of the 57 that completed or were terminated, 17 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 68 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
16 studies in Head and Neck Neoplasms by Sanofi: none open now, none under way, none of them phase 3. Of 14 finished, 1 (7%) have results posted.
Among the 16 studies in Head and Neck Neoplasms by Sanofi, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 1998, is one of 2 in phase 2/3, and was the 8th registered.
Sanofi’s Head and Neck Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 68 studies testing docetaxel in Head and Neck Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 16 in Head and Neck Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to compare time to progression and overall survival after treatment with Taxotere plus cisplatin versus cisplatin plus 5-FU (PF treatment group) in the first line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Inclusion Criteria:
Patients with or cytologically documented squamous cell carcinoma of the head and neck (SCCHN) (eligible primary sites: oral cavity, oropharynx, hypopharyx, or larynx) presenting with locally recurrent and/or disease, with at least 1 unidimensionally or bidimensionally .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Taxotere 75 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by cisplatin 75 mg/m² administered as a 30-minute to 3-hour infusion on Day 1
Drug: docetaxel (XRP6976) · Drug: cisplatin
Cisplatin 100 mg/m², 30-minute to 3-hour infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 1000 mg/m²/day from Day 1 to Day 5
Drug: cisplatin · Drug: 5-fluorouracil (5-FU)
Taxotere 85 mg/m², one-hour IV infusion on Day 1 of each 3-week cycle followed by the continuous infusion of 5-FU 750 mg/m²/day from Day 1 to Day 5 Arm only in the phase II part of the study
Drug: docetaxel (XRP6976) · Drug: 5-fluorouracil (5-FU)
Also known as: Taxotere
time to progression
Time frame: up to 5 years
overall survival, overall response rate (complete response + partial response), duration of response, and time to treatment failure
Time frame: up to 5 years
The record gives a start of Jan 1998, a primary completion of Jun 2003 and a completion of Jun 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Docetaxel · Cisplatin · Fluorouracil